Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunochemotherapy in advanced neuroblastoma.

T F Necheles, A R Rausen, F H Kung

    Cancer
    |April 1, 1978
    PubMed
    Summary

    This study suggests that adding MER/BCG to chemotherapy may improve survival for advanced neuroblastoma patients. Chemotherapy alone showed shorter remission durations compared to the combination therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    ORMOCHALCs: organically modified chalcogenide polymers for infrared optics.

    Chemical communications (Cambridge, England)·2016
    Same author

    Introduction.

    Pediatric annals·2014
    Same author

    Introduction.

    Pediatric annals·2014
    Same author

    Infrared evanescent-absorption spectroscopy with chalcogenide glass fibers.

    Applied optics·2010
    Same author

    Successful unrelated donor cord blood transplantation for adult sickle cell disease and Hodgkin lymphoma.

    Bone marrow transplantation·2009
    Same author

    Effect of temperature on the absorption loss of chalcogenide glass fibers.

    Applied optics·2008

    Area of Science:

    • Pediatric Oncology
    • Immunotherapy
    • Cancer Research

    Background:

    • Neuroblastoma is a common childhood cancer.
    • Advanced stages (III and IV) have a poorer prognosis.
    • Standard chemotherapy regimens are used for treatment.

    Purpose of the Study:

    • To evaluate the efficacy of a three-drug chemotherapy regimen for advanced neuroblastoma.
    • To assess the impact of adding MER/BCG (an immunostimulatory agent) to this regimen.
    • To compare survival durations and remission rates between the two treatment arms.

    Main Methods:

    • A nonrandomized pilot study involving 22 children with Stage III/IV neuroblastoma.
    • Treatment groups: (1) Vincristine, Adriamycin, Cyclophosphamide (chemotherapy alone); (2) Chemotherapy plus MER/BCG.
    • Data collected on duration of survival and remission.

    Main Results:

    • The median duration of response was less than one year for chemotherapy alone.
    • Children receiving chemotherapy plus MER/BCG showed a median duration of complete remission not reached at 24 months.
    • Preliminary data suggest improved survival with the addition of MER/BCG.

    Conclusions:

    • The addition of MER/BCG to standard chemotherapy may enhance survival duration in advanced neuroblastoma.
    • Further investigation is warranted to confirm these findings in larger, randomized trials.
    • Immunotherapy combined with chemotherapy shows promise in pediatric cancer treatment.

    Related Experiment Videos